Disorders of the JAK/STAT pathway in T cell lymphoma pathogenesis: Implications for immunotherapy

Annual Review of Immunology

Volumn 35, Issue , 2017, Pages 533-550

  Waldmann, Thomas A ^a   Chen, Jing ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

JAK STAT; T cell lymphoma; c cytokines

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE; STAT PROTEIN; STAT3 PROTEIN; STAT5B PROTEIN; ANTINEOPLASTIC AGENT; CYTOKINE; CYTOKINE RECEPTOR; ENZYME INHIBITOR; MONOCLONAL ANTIBODY;

CANCER IMMUNOTHERAPY; GENE MUTATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CYTOKINES; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JANUS KINASES; LYMPHOMA, T-CELL; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85018268489     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-110416-120628     Document Type: Review

References (95)

1. Rochman Y, Spolski R, Leonard WJ. 2009. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9(7):480-90
2. Leonard WJ. 2001. Cytokines and immunodeficiency diseases. Nat. Rev. Immunol. 1(3):200-8
3. Kovanen PE, Leonard WJ. 2004. Cytokines and immunodeficiency diseases: critical roles of the γcdependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202:67-83
4. Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6(8):595-601
5. Waldmann TA. 2015. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3(3):219-27
6. Rui LX, Emre NCT, Kruhlak MJ, Chung HJ, Steidl C, et al. 2010. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18(6):590-605
7. Chen E, Staudt LM, Green AR. 2012. Janus kinase deregulation in leukemia and lymphoma. Immunity 36(4):529-41
8. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, et al. 2009. JAK2 phosphorylates histone H3Y41 and excludes HP1afrom chromatin. Nature 461(7265):819-22
9. Yan J, Li B, Lin B, Lee PT, Chung TH, et al. 2016. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood 128(7):948-58
10. Wegrzyn J, Potla R, Chwae Y-J, Sepuri NBV, Zhang Q, et al. 2009. Function of mitochondrial Stat3 in cellular respiration. Science 323(5915):793-97
11. Vainchenker W, Constantinescu SN. 2013. JAK/STAT signaling in hematological malignancies. Oncogene 32(21):2601-13
12. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, et al. 1995. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269(5220):79-81
13. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, et al. 2012. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366(20):1905-913
14. Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, et al. 2012. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120(15):3048-57
15. Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA. 2013. STAT3mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 27(11):2244-47
16. Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, et al. 2015. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27(4):516-32
17. Chiarle R, Simmons WJ, Cai HY, Dhall G, Zamo A, et al. 2005. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11(6):623-29
18. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, et al. 2003. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK-anaplastic large cell lymphoma. Clin. Cancer Res. 9(10):3692-699
19. Kucuk C, Jiang B, Hu XZ, Gaulard P, Zhang Y, et al. 2013. Frequent activating mutations of JAK-STAT pathway genes in natural killer cell lymphomas. Blood 122(21):812 (Abstr.)
20. Bouchekioua A, Scourzic L, de Wever O, Zyang Y, Cervera P, et al. 2014. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 28(2):338-48
21. Coppo P, Gouilleux-Gruart V, Huang Y, Bouhlal H, Bouamar H, et al. 2009. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 23(9):1667-678
22. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, et al. 2012. Janus kinase 3-activating mutations identified in natural/killer/T-cell lymphoma. Cancer Discov. 2(7):591-97
23. Kucuk C, Jiang B, Hu XZ, Zhang WY, Chan JKC, et al. 2015. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells. Nat. Commun. 6:6025
24. Nicolae A, Xi L, Pittaluga S, Abdullaev Z, Pack SD, et al. 2014. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 28(11):2244-48
25. Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, et al. 2014. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 53(4):309-16
26. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, et al. 2014. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124(9):1460-72
27. Bellanger D, Jacquemin V, Chopin M, Pierron G, Bernard OA, et al. 2014. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28(2):417-19
28. Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, et al. 2001. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15(5):787-93
29. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, et al. 1996. Activation of Jak/STAT proteins involved in signal transduction pathwaymediated by receptor for interleukin 2 inmalignantTlymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. PNAS 93(17):9148-53
30. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, et al. 2015. Genomic landscape of cutaneous T cell lymphoma. Nat. Genet. 47(9):1011-19
31. Zhang JH, Ding L, Holmfeldt L, Wu G, Heatley SL, et al. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157-63
32. Odejide O, Weigert O, Lane AA. 2014. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123(9):1293-96
33. Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BKR, et al. 1997. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. PNAS 94(25):13897-902
34. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, et al. 2015. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47(11):1304-15
35. Lacronique V, Boureux A, DellaValle V, Poirel H, Quang CT, et al. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278(5341):1309-12
36. Schwaller J, Parganas E, Wang DM, Cain D, Aster JC, et al. 2000. Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell 6(3):693-704
37. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, et al. 2000. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95(12):3891-99
38. Feldman AL, Vasmatzis G, Asmann YW, Davila J, Middha S, et al. 2013. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma. Genes Chromosomes Cancer 52(11):1097-102
39. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054-61
40. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, andmyeloidmetaplasia with myelofibrosis. Cancer Cell 7(4):387-97
41. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17):1779-90
42. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144-48
43. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. 2015. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu. Rev. Med. 66:311-28
44. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, et al. 2012. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366(9):787-98
45. Firwana B, Sonbol MB, Diab M, Raza S, Hasan R, et al. 2016. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: amixed-treatment comparison. Int. J. Cancer 138(6):1545-53
46. O'Shea JJ, Holland SM, Staudt LM. 2013. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368(2):161-70
47. Schatz JH, Horwitz SM, Lunning MA, Dolgalev I, Huberman K, et al. 2013. Next-generation sequencing suggests complex, heterogeneous pathogenesis in peripheral T-cell lymphoma unspecified. Blood 122(21):843 (Abstr.)
48. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. 2008. Therapeutic targeting of Janus kinases. Immunol. Rev. 223:132-42
49. Ju W, Zhang ML, Jiang JK, Thomas CJ, Oh U, et al. 2011. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 117(6):1938-46
50. Wei M, Koshy N, van Besien K, Inghirami G, Horwitz SM. 2015. Refractory T-cell prolymphocytic leukemia with JAK3mutation: in vitro and clinical synergy of tofacitinib and ruxolitinib. Blood 126(23):5486 (Abstr.)
51. Conlon KC, Waldmann TA. 2016. Ruxolitinib for adult T-cell leukemia. Clin. Study Rec. NCT01712659, updated Sep. 28. Natl. Inst. Health. https://clinicaltrials.gov/ct2/show/NCT01712659
52. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, et al. 2002. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21(7):1038-47
53. Roskoski R Jr. 2013. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol. Res. 68(1):68-94
54. Chen J, Petrus M, Bryant BR, Nguyen VP, Stamer M, et al. 2008. Induction of the IL-9 gene byHTLV-1 Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111(10):5163-72
55. Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, et al. 2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adultT-cell leukemia. Blood 116(26):5948-56
56. Filippakopoulos P, Muller S, Knapp S. 2009. SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr. Opin. Struct. Biol. 19(6):643-49
57. Heim MH, Kerr IM, Stark GR, Darnell JE. 1995. Contribution of STATSH2groups to specific interferon signaling by the Jak-STAT pathway. Sci.267(5202):1347-49
58. McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, et al. 2015. Whole-genome sequening reveals oncogenic mutations in mycosis fungoides. Blood 126(4):508-19
59. Rajala HLM, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, et al. 2013. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121(22):4541-50
60. Rajala HLM, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S. 2014. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann. Med. 46(3):114-22
61. Saharinen P, Silvennoinen O. 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277(49):47954-63
62. Saharinen P, Takaluoma K, Silvennoinen O. 2000. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell Biol. 20(10):3387-95
63. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. 2011. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 118(14):3911-21
64. Yamashita Y, Shimada A, Yamada T, Yamaji K, Hon T, et al. 2013. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute lymphoblastic leukemia. Pediatr. Blood Cancer 60(10):1587-92
65. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, et al. 2008. Somatically acquired JAK1mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205(4):751-58
66. Mullighan CG, Zhang JH, Harvey RC, Collins-Underwood JR, Schulman BA, et al. 2009. JAK mutations in high-risk childhood acute lymphoblastic leukemia. PNAS 106(23):9414-18
67. Lu XH, Levine R, Tong W, Wernig G, Pikman Y, et al. 2005. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. PNAS 102(52):18962-67
68. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, et al. 2009. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor ahomodimers. J. Biol. Chem. 284(11):6773-81
69. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, et al. 2011. Gain-of-function mutations in interleukin-7 receptor-a (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208(5):901
70. Zenatti PP, Ribeiro D, Li WQ, Zuurbier L, Silva MC, et al. 2011. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43(10):932-39
71. Tendler CL, Greenberg SJ, Blattner WA, Manns A, Murphy E, et al. 1990. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. PNAS 87(13):5218-22
72. Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA. 1998. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-κB site. PNAS 95(5):2452-57
73. Leroy S, Dubois S, Tenaud I, Chebassier N, Godard A, et al. 2001. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br. J. Dermatol. 144(5):1016-23
74. Dobbeling U, Dummer R, Laine E, Potoczna N, Gin JZ, Burg G. 1998. Interleukin-15 is an autocrine/ paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92(1):252-58
75. Mishra A, Kwiatkowski S, Sullivan L, Grinshpun L, Russo G, et al. 2015. Epigenetic disruption of ZEB1 binding causes constitutive activation of IL-15 in cutaneous T-cell lymphoma. Blood 126(23):2
76. Nakahata S, Yamazaki S, Nakauchi H, Morishita K. 2010. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-β1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene 29(29):4157-69
77. Jain S, Chen J, Nicolae A, Wang HS, Shin DM, et al. 2015. IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma. Am. J. Pathol. 185(11):3102-14
78. Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, et al. 2010. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 42(6):530-35
79. Kleppe M, Soulier J, Asnafi V, Mentens N, Hornakova T, et al. 2011. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood 117(26):7090-98
80. Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, et al. 2012. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 119(19):4476-79
81. Alexander WS. 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2(6):410-16
82. Kucuk C, Hu X, Jiang B, Klinkebiel D, Geng HM, et al. 2015. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma.Clin. Can. Res. 21(7):1699-711
83. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, et al. 2005. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52(9):2686-692
84. Waldmann TA. 2007. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 27(1):1-18
85. Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, et al. 2014. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin. Immunol. 155(2):176-87
86. Nata T, Basheer A, Cocchi F, van Besien R, Massoud R, et al. 2015. Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum. J. Biol. Chem. 290(37):22338-51
87. Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, et al. 2015. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42(5):826-38
88. O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F. 1997. Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J. Clin. Immunol. 17(6):431-47
89. Leonard WJ, O'Shea JJ. 1998. JAKS ANDSTATS: Biological implications. Annu. Rev. Immunol. 16:293-322
90. Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, et al. 2015. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia 29(12):2427-29
91. Haan C, Rolvering C, Raulf F, Kapp M, Druckes P, et al. 2011. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem. Biol. 18(3):314-23
92. Smith GA, Uchida K, Weiss A, Taunton J. 2016. Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling. Nat. Chem. Biol. 12(5):373-79
93. Buettner R, Mora LB, Jove R. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8(4):945-54
94. Zhang ML, Griner LAM, Ju W, Duveau DY, Guha R, et al. 2015. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. PNAS 112(40):12480-85
95. Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, et al. 2015. Targeting mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia 29(1):237-41